EAACI Congress 2023
BackFlash talks on angioedema
Sunday 11 Jun, 14:00 PM -
15:30 PM CEST
Hall Y 11+12
Flash Talks
14:00
Multicentric observational study on safety and tolerability of Covid 19 vaccines in patients with angioedema with C1 inhibitor deficiency: data from Italian Network on Hereditary and Acquired Angioedema (ITACA)
14:07
Efficacy and safety of lanadelumab in pediatric patients aged 2 to <12 years: subgroup analyses from the SPRING Study
14:14
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
14:21
Mutant plasminogen in hereditary angioedema is bypassing FXII/kallikrein to generate bradykinin
14:28
Real-world Effectiveness of Lanadelumab in European Patients with HAE Type I/II: Results from the Retrospective INTEGRATED Study
14:35
A global consensus on the definition, acronyms, nomenclature, and classification of angioedema (the DANCE initiative)
14:42
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
14:49
Real-world Burden of Illness in Patients with Hereditary Angioedema Type I and II
14:56
Remaining burden of hereditary angioedema (HAE) attacks despite modern long-term prophylaxis
15:03
Assesment of endothelial dysfunction in hereditary angioedema
15:10
Burden of hereditary angioedema: Findings from a multinational patient survey in Argentina and Colombia
15:17
Burden of hereditary angioedema: Findings from a multinational survey of caregivers for pediatric and adult patients in Argentina and Colombia
15:24
Management of Hereditary angioedema with normal C1Inh : About a series of 149 French cases
15:31
The impact of puberty on onset, frequency, location and severity of attacks in Hereditary Angioedema due to C1-inhibitor deficiency: a survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA)
